Pharmacokinetics of plasma‐derived vs. recombinantFVIIIconcentrates: a comparative study-Reference-Cited by-同舟云学术

Pharmacokinetics of plasma‐derived vs. recombinantFVIIIconcentrates: a comparative study

Published:2014-10-02 Issue:2 Volume:21 Page:204-209
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:Haemophilia

Author:

Morfini M.¹,Marchesini E.²,Paladino E.¹,Santoro C.³,Zanon E.⁴,Iorio A.⁵

Affiliation:

1. Agency for Haemophilia University Hospital of Florence Florence Italy

2. Haemophila Centre of University Hospital Santa Maria della Misericordia Perugia Italy

3. Haematology Department of Biotechnology and Haematology Sapienza University of Rome Rome Italy

4. Haemophilia Center of University Hospital Padua Italy

5. Health Information Research Unit Department of Clinical Epidemiology and Biostatistic and Hemophilia Clinic Department of Medicine McMaster University Hamilton ON Canada

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hae.12550

Reference28 articles.

1. Musculoskeletal complications of haemophilia: the joint

2. Prophylaxis in the haemophilia population

3. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia

4. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy

5. In vivo recovery of factor VIII and factor IX: intra- and interindividual variance in a clinical setting

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bioequivalence of recombinant factor VIII products: a position paper from the Italian Association of Hemophilia Centers;BLOOD TRANSFUS-ITALY;2023

2. Managing Relevant Clinical Conditions of Hemophilia A/B Patients;Hematology Reports;2023-06-07

3. Inter-individual variability in pharmacokinetics and clinical features in pediatric patients with severe hemophilia A;Thrombosis Research;2022-05

4. Managing Severe Hemophilia A in Children: Pharmacotherapeutic Options;Pediatric Health, Medicine and Therapeutics;2022-02

5. Perspective – The case for zero bleeds and drug bioequivalence in the treatment of congenital hemophilia A in 2021;Blood Reviews;2021-11